FAQ

Fluvoxamine Maleate 50 MG Oral Tablet

Known as: FLUVOXAMINE MALEATE 50 mg ORAL TABLET, COATED [fluvoxamine maleate], FLUVOXAMINE MALEATE 50MG TAB, FLUVOXAMINE MALEATE 50 mg ORAL TABLET, FILM COATED 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2010
01220032010

Related topics

Related topics

30 relations
Depressive disorderDrug AllergyFD&C yellow no. 6Fluvoxamine Maleate
(More)

Broader (1)

Fluvoxamine

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Fluvoxamine Maleate 50 MG Oral Tablet
Depressive disorder
Drug Allergy
Silicon Dioxide
Polyethylene Glycols
Obsessive-Compulsive Disorder

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects.
Elevating serotonin (5-HT) levels with selective serotonin reuptake inhibitors (SSRIs) is the most widely used treatment for… (More)
Is this relevant?
2010
2010
RGS inhibition at Gαi2 selectively potentiates 5-HT1A–mediated antidepressant effects
Elevating serotonin (5-HT) levels with selective serotonin reuptake inhibitors (SSRIs) is the most widely used treatment for… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2009
2009
Management of obsessive-compulsive disorder with fluvoxamine extended release
The pharmacodynamic properties of fluvoxamine maleate include the modulation of different populations of serotonergic… (More)
  • table 1
Is this relevant?
Review
2008
Review
2008
Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia.
Specific serotonin reuptake inhibitors are currently recommended as first-line treatments for obsessive-compulsive disorder (OCD… (More)
Is this relevant?
2008
2008
Chronic Treatment with Fluvoxamine Stimulates Phosphorylation of Ser and Thr of Akt in the Rat Cerebral Cortex
The clinical therapeutic e#ect of most antidepressant drugs only develops after several weeks of administration, but little is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.
BACKGROUND Generalized social anxiety disorder is a highly prevalent anxiety disorder with deleterious effects on social and… (More)
Is this relevant?
2004
2004
A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder.
This was a randomized double-blind placebo-controlled multicenter study to assess the efficacy, safety, and tolerability of… (More)
Is this relevant?
2003
2003
Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial.
Fluvoxamine CR has been reported effective in the short-term (12-wk) treatment of generalized social anxiety disorder (social… (More)
  • table 1
  • figure 2
  • table 2
Is this relevant?
2003
2003
A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
OBJECTIVE The aim of this 12-week, double-blind, flexible-dose, placebo-controlled, parallel-arm, multicenter trial was to… (More)
Is this relevant?